Aura Biosciences Inc

AURA

5.350USD

-0.060-1.11%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

Aura Biosciences Inc's Score

Industry at a Glance

Industry Ranking

240 / 501

Overall Ranking

427 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 6 analysts

Buy

Current Rating

20.750

Target Price

+283.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aura Biosciences Inc Highlights

StrengthsRisks

Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing precision immunotherapies to treat solid tumors designed to preserve the function of the afflicted organ with cancer. It is developing a pipeline of virus-like drug conjugates (VDCs), a class of drugs with a dual mechanism of action, that promote cancer cell death by both the delivery of the cytotoxic payload to generate acute necrosis and activation of a secondary immune mediated response. Its lead candidate, bel-sar, is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. Bel-sar consists of a human papillomavirus (HPV)-derived virus-like particle (VLP), conjugated to hundreds of infrared laser-activated molecules. It is evaluating the bel-sar in a Phase III CoMpass trial for the first line treatment of early-stage choroidal melanoma.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -3.13, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.54M shares, decreasing 2.75% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 6.09K shares of this stock.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 5.85, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -3.13, which is -17.61% below the recent high of -2.58 and -207.01% above the recent low of -9.61.

Score

Industry at a Glance

Previous score

5.85

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 240/501

No Data

The company’s current earnings forecast score is 8.33, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Aura Biosciences Inc is 21.00, with a high of 22.00 and a low of 19.00.

Score

Industry at a Glance

Previous score

8.33

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.66, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 6.63 and the support level at 5.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.55

Change

0.11

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 84.58%, representing a quarter-over-quarter increase of 8.31%. The largest institutional shareholder is The Vanguard, holding a total of 2.48M shares, representing 3.99% of shares outstanding, with 3.98% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Matrix Capital Management Company, LP

6.92M

--

Frazier Life Sciences Management, L.P.

5.10M

--

Adage Capital Management, L.P.

4.88M

--

Long Focus Capital Management LLC

4.62M

+39.16%

Suvretta Capital Management, LLC

4.37M

+43.03%

Medicxi Ventures (UK) LLP

3.04M

--

The Vanguard Group, Inc.

Star Investors

2.48M

+26.90%

BlackRock Institutional Trust Company, N.A.

2.77M

-13.28%

Franklin Advisers, Inc.

2.34M

+5.88%

Nantahala Capital Management, LLC

2.12M

+67.05%



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Aura Biosciences Inc

AURA

4.58 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment